Quality Index (PSQI). However, polysomnographic (PSG) studies show meagre evidence of sleep disturbance on standard physiological measures. The present aim was to analyse self-reported sleep quality in TMD as a function of myofascial pain, PSG parameters and depressive symptomatology. PSQI scores from 124 women with myofascial TMD and 46 matched controls were hierarchically regressed onto TMD presence, ratings of pain intensity and pain-related disability, in-laboratory PSG variables and depressive symptoms (Symptoms Checklist-90). Relative to controls, TMD cases had higher PSQI scores, representing poorer subjective sleep and more depressive symptoms (both P < 0Á001). Higher PSQI scores were strongly predicted by more depressive symptoms (P < 0Á001, R 2 = 26%). Of 19 PSG variables, two had modest contributions to higher PSQI scores: longer rapid eye movement latency in TMD cases (P = 0Á01, R 2 = 3%) and more awakenings in all participants (P = 0Á03, R 2 = 2%).
SUMMARY Patients with temporomandibular disorder (TMD) report poor sleep quality on the Pittsburgh Sleep
Quality Index (PSQI). However, polysomnographic (PSG) studies show meagre evidence of sleep disturbance on standard physiological measures. The present aim was to analyse self-reported sleep quality in TMD as a function of myofascial pain, PSG parameters and depressive symptomatology. PSQI scores from 124 women with myofascial TMD and 46 matched controls were hierarchically regressed onto TMD presence, ratings of pain intensity and pain-related disability, in-laboratory PSG variables and depressive symptoms (Symptoms Checklist-90). Relative to controls, TMD cases had higher PSQI scores, representing poorer subjective sleep and more depressive symptoms (both P < 0Á001). Higher PSQI scores were strongly predicted by more depressive symptoms (P < 0Á001, R 2 = 26%). Of 19 PSG variables, two had modest contributions to higher PSQI scores: longer rapid eye movement latency in TMD cases (P = 0Á01, R 2 = 3%) and more awakenings in all participants (P = 0Á03, R 2 = 2%).
After accounting for these factors, TMD presence and pain ratings were not significantly related to PSQI scores. These results show that reported poor sleep quality in TMD is better explained by depressive symptoms than by PSG-assessed sleep disturbances or myofascial pain. As TMD cases lacked typical PSG features of clinical depression, the results suggest a negative cognitive bias in TMD and caution against interpreting self-report sleep measures as accurate indicators of PSG sleep disturbance. Future investigations should take account of depressive symptomatology when interpreting reports of poor sleep.
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Background
Patients with temporomandibular disorders (TMDs) comprise approximately 10% of the population are predominantly female and frequently present with chronic pain in the masticatory muscles and temporomandibular joint (1) . Numerous studies show poor self-reported sleep quality in patients with TMD using the Pittsburgh Sleep Quality Index (PSQI) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . The PSQI combines 18 sleep history items into a global score, which, in excess of 5, is indicative of clinically poor sleep (12) . In uncontrolled TMD samples, mean PSQI scores ranged approximately between 7 and 11, depending on the type of myofascial pain and psychosocial factors, such as exposure to stressors (2-6). Case-control studies with and without matching report significantly higher PSQI scores in patients with TMD than controls (7-11), providing further evidence for self-reported, or subjective, sleep disturbance in TMD.
Some studies report higher levels of self-reported pain among TMD patients with elevated PSQI scores (2, 6, 9) , suggesting that pain is a causal factor in sleep impairment. However, other studies employing the PSQI do not evidence a connection between poor sleep and pain intensity (4, 5) . This lack of consistency in the PSQI-pain relationship in the TMD literature suggests that factors other than pain may contribute to subjectively poor sleep; that is, the TMD diagnosis may be a marker for some correlated factor that better explains reports of impaired sleep.
Several studies indicate that patients with TMD reporting poor sleep on the PSQI also report more symptoms of depression, anxiety and distress (2-4, 6, 7, 9) . Additionally, recent evaluations of non-clinical samples of participants without a history of pain or sleep disorders show an association between PSQI scores and reports of depressive symptoms and distress, but not between PSQI data and such objective sleep measures as polysomnography (PSG) and actigraphy (13, 14) . These data suggest that the psychological distress often associated with chronic pain may account for self-reported poor sleep in patients with TMD.
While the literature is consistent in showing subjective reports of impaired sleep in patients with TMD, PSG evaluations of physiological variables generally fail to provide objective evidence of sleep disturbance. Two early investigations that employed small samples and restrictive selection criteria found no differences in PSG parameters between patients with TMD and controls (15, 16) . A larger, yet uncontrolled, study of patients with TMD revealed an essentially normal sleep architecture, based on measures such as sleep onset latency, rapid eye movement (REM) sleep latency, sleep efficiency and sleep stage distribution (17, 18) A recent PSG study of a large TMD sample showed mild, albeit significant, increases in the percentage of stage N1 sleep (N1%) and in the frequency of respiratory effortrelated arousals (RERAs) relative to demographically matched controls of similar body mass index (BMI); patients with TMD were within normal limits on all other PSG variables (19) . Thus, standard objective measurements of sleep quality fail to support the conclusion of impaired sleep quality in patients with TMD that is suggested by self-reports.
The present aim was to evaluate how self-report ratings of sleep quality vary as a function of pain intensity, PSG measures, and reports of depressive symptoms in a large sample of women with TMD and demographically matched controls. It was hypothesised that subjectively poor sleep in TMD cases would be better explained by depressive symptoms than by objective sleep measures or pain severity.
Materials and methods

Participants
Participants were recruited at the New York University College of Dentistry (NYUCD) based on the Research Diagnostic Criteria for TMD with myofascial pain (RDC/TMD Group I) (20) . Only women participated in the study, as patients with TMD are predominantly female (1) . Control participants without myofascial TMD, matched for age, socio-economic status and self-identified race and ethnicity, were recruited from those seeking care at the NYUCD dental clinics and among acquaintances of participating cases. Participants with potential sources of facial pain other than TMD and with certain conditions concerning pain or sleep, for example diabetes or the use of an appliance for sleep disordered breathing, were excluded. More detailed descriptions of inclusion/exclusion criteria have been reported (19, 21) .
The final sample included 124 TMD cases and 46 controls. Approximately 63% self-identified as White, 14% as Black and 23% as 'other'; 23% self-identified as Hispanic. The mean AE s.d. age was 39Á2 AE 14Á6 years, the mean duration of education was 15 AE 2Á2 years, and the mean BMI was 25Á0 AE 5Á1 kg m
À2
. Cases and controls were similar in both exclusion rates and demographic composition, as reported elsewhere (19, 21) .
Procedures
Participants were consented, examined and interviewed at the NYU School of Medicine. Included participants provided self-report measures of sleep and mood and were scheduled to undergo two consecutive nocturnal PSG recordings at an affiliated sleep laboratory.
Self-report myofascial pain variables. Control participants free from myofascial pain, as ascertained during the initial evaluation, did not provide pain ratings. For TMD cases, a standardised RDC/TMD pain history questionnaire was used to ascertain the length and severity of pain, and pain-related functional impairment.
To measure pain severity, participants rated (i) pain at the time of the interview, (ii) their worst pain and (iii) their average pain in the preceding 6 months, using a numeric scale from 0 ('no pain') to 10 ('pain as bad as it could be'). The mean of three ratings was the characteristic pain intensity (CPI) (22) .
For functional impairment, participants rated the degree of pain interference with regard to the ability to perform (i) daily activities, (ii) social activities and (iii) work in the preceding 6 months, using a scale from 0 ('no interference/no change') to 10 ('unable to carry on activities/extreme change'). The mean of these three ratings was the functional pain-related disability (FPD).
Self-report depression. The Symptom Checklist 90 (SCL-90) was used to evaluate depressive symptoms in all participants during the preceding month. The SCL-90 encompasses 19 cognitive and behavioural symptoms associated with depression, with the severity of each rated on a 0-4 scale; the mean of these ratings is the depression score (SCL-90-D) (23).
Self-report sleep quality. The PSQI was used to measure subjective sleep quality in all participants during the preceding month. The PSQI utilises 18 items to obtain estimates of quality and duration of sleep, sleep onset, frequencies of various sleep-related disturbances and daytime sequelae. It yields seven 'components', a sum of which is a global score ranging 0-21, where higher values represent more disturbed sleep (12) . A psychometric analysis of the PSQI in patients with TMD revealed good intercomponent and test-retest reliability, and convergent validity with two sleep-related items from the General Health Questionnaire (24) .
PSG variables. Two consecutive nocturnal PSG recordings were conducted for each participant on SomnoStarPro acquisition system* using a standard clinical PSG montage with additional electromyography (EMG) leads for a total of 22 channels. Detailed descriptions of the recording and scoring procedures are reported elsewhere (19, 21) . To minimise the first night effect, PSG data from the second night were used for analysis, except for nine cases and one control whose second night data were not available due to technical failure or attrition.
Based on scored PSG data, the following objective measures of sleep architecture and continuity were used as follows: total sleep time (TST, in minutes), wake after sleep onset (WASO, in minutes), sleep efficiency (SEF = total sleep time/time in bed 9 100%), sleep onset latency (SOL, time from lights out to sleep onset, in minutes), number of awakenings (AWAKE), number of sleep stage shifts into stage N1 from any other stage of sleep (N1Shift), percentages of sleep stages N1, N2, N3 and REM sleep (N1%, N2%, N3% and REM%, respectively; time in a given sleep stage/ TST 9 100%), REM sleep latency (REMLat, time from sleep onset to REM sleep onset, in minutes), and index values (number of respective events per hour of sleep) for the following events: total arousals (TotAr, transient encephalographic changes towards wakefulness during sleep), spontaneous arousals (SponAr), respiratory arousals (RespAr, combined arousals associated with apnoeas, hypopneas and RERAs), RERAs, apnoeas and hypopneas (AHI), combined apnoeas, hypopneas and RERAs (RDI), periodic limb movements (PLM) and PLM-related arousals (PLMAr).
Data analysis
Group differences on the PSQI and the SCL-90-D were evaluated with independent samples t-tests. The PSQI scores were modelled in a hierarchical linear regression that first entered case-control status, then a stepwise selection of significant PSG variables, followed by entry of the SCL-90-D. Another regression model was fit for TMD cases only, predicting the PSQI based on a stepwise selection of CPI and FPD, a stepwise entry of PSG variables and the SCL90-D. The alpha level for all analyses was set at 0Á05. All analysis used IBM SPSS.
Results
On average, participants with TMD suffered from pain for over 10 years. The mean pain intensity was moderate (CPI mean = 5Á2 AE 1Á7), while the functional effect of pain was mild, with a positive skew (FPD mean = 1Á7 AE 2Á2, median = 0Á7).
Compared to controls, TMD cases reported significant, albeit mild, elevations in subjective sleep disturbance (the PSQI: mean cases = 6Á0 AE 3Á5 versus mean controls = 3Á5 AE 2Á5, df = 110, t = 5Á2, P < 0Á001) and depressive symptomatology (the SCL-90-D: mean cases = 1Á00 AE 0Á78 versus mean controls = 0Á34 AE 0Á33, df = 165, t = 7Á7, P < 0Á001). Case-control comparisons on PSG measures have been reported earlier (23) .
Pittsburgh Sleep Quality Index scores were modelled as a function of case-control status, characteristics of the PSG and depressive symptomatology (Table 1) . Zero-order correlations showed significant relationships between PSQ scores and case-control status, many parameters from the PSG study and SCL-90-D scores. In Model 1, TMD status accounted for about 11% of variance in the PSQI, or average scores that were about 2Á5 units higher among cases. In Model 2, TMD effect was retained when AWAKE, the strongest PSG predictor of PSQI scores, was entered. Model 2 shows that numerous zero-order 
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PSG-PSQI relationships could be captured by the variance represented by AWAKE, and the contribution of awakenings to subjective sleep quality overlaps with other PSG measures in all participants. When SCL-90-D scores were entered in Model 3, case-control status effect, diminished to 0Á7 units, was no longer significant. However, there was little change in the adjusted AWAKE-PSQI relationship, indicating that awakenings are related to the PSQI in a different way than depressive symptoms. Depressive symptoms accounted for 26% (P < 0Á001), and AWAKE accounted for 2% (P = 0Á03) of the variance in PSQI responses. This is further illustrated in Fig. 1 , which shows that PSQI scores remain associated with SCL-90-D scores after adjusting for the effects of the TMD status and AWAKE. Thus, the case-control difference in PSQI scores can be attributed to their different levels of depressive symptoms; the remaining explained variability in PSQI scores can be attributed to awakenings regardless of the case-control status. Among the TMD cases (Table 2) , Model 1 showed collinearity between the FPD and CPI scores; CPI was the stronger predictor, accounting for about 9% of the PSQI variance, and was associated with about a 0Á6 point increase in PSQI scores for every 1 point increase in pain ratings. Several PSG measures had zero-order correlations with PSQI scores; however, in Model 2, they could all be captured by REM latency, where PSQI scores increased 0Á1 units for every 10 min increase in REM latency, independently of the CPI effect. In Model 3, the SCL-90-D accounted for 24% (P < 0Á001) of the PSQI variance, and REM latency, for 3% (P = 0Á01), while the CPI effect was no longer significant. This is further illustrated in Fig. 2 , which shows that PSQI scores remain associated with SCL-90-D scores after adjusting for the effects of the CPI and REM latency. Identical results were obtained when using a modified SCL-90-D scoring without its three sleep-related items and a modified PSQI scoring without one pain-related item, eliminating 'structural confounding' in the response scales. Together, these analyses suggest that depressive symptoms covary with pain ratings and provide better explanation than pain for reports of disturbed sleep.
Discussion
A sample of women with myofascial TMD was evaluated for pain intensity and functional effects, depressive symptomatology using the SCL-90, objective sleep parameters using 2-night PSG recordings and subjective sleep quality using the PSQI. In this largest PSG-evaluated TMD sample to date, moderate levels of chronic myofascial pain intensity were consistent with levels reported in previous studies (2-8, 10, 11, 15) . Reports of sleep quality were significantly worse 
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among cases than in demographically matched controls, and there was little concordance between PSQI scores and PSG indicators. As hypothesised, the results showed that reports of poor sleep quality were better accounted for by symptoms of depression than by pain or objective sleep measures.
Depressive symptoms were significantly higher in TMD cases than controls, and the relationship between the PSQI and TMD status disappeared when depressive symptomatology was taken into account. Similarly, among TMD cases the association between pain intensity and sleep ratings disappeared when depressive symptomatology was taken into account. This suggests that depressed mood, which contains effects related to pain intensity, provides the better explanation for subjective ratings of poor sleep. From multiple standard PSG parameters, only two measures accounted for a small portion of additional variance in the PSQI (Tables 1 and 2) : awakenings in all participants, and REM latency among cases. As previously reported for this sample, the frequency of awakenings was not statistically different between TMD cases and TotAr  0Á09  0Á15  0Á93  0Á51  SponAr  0Á10  0Á46  0Á79  0Á78  RespAr  0Á11  0Á12  0Á71  0Á74  RERA  0Á14  0Á06  0Á92  0Á88  AHI  0Á09  0Á17  0Á88  0Á80  RDI  0Á14  0Á06  0Á86  0Á78  PLM  0Á07  0Á22  0Á93  0Á27  PLMAr  0Á07  0Á24  0Á79  0Á75  SCL- control, and the mean REM sleep latency in TMD cases, albeit longer, remained within normal limits (19) . In the present analysis, depressive symptomatology, elevated in TMD cases relative to controls, explained by far the largest portion of the variance in self-reported sleep quality, approximately 25% (Tables 1 and 2 , Figs 1 and 2) . The PSQI, a psychometrically sound self-report sleep measure widely used in TMD population (24) , failed to show much of a relationship with PSG measures in the present study. The general paucity of PSQI-PSG relationships in all participants is consistent with studies examining PSQI scores in relation to objective sleep measures in non-pain samples (13, 14) . Taken together, these data do not support inferences of disturbed PSG sleep (e.g. altered sleep stage distribution or duration) on the basis of PSQI data alone, although wider-scale PSG evaluations of patients with TMD would be needed to corroborate this conclusion.
The lack of PSG evidence of disturbed sleep notwithstanding, the pattern presented by TMD cases -poor subjective sleep largely explained by depressive symptomatology and accompanied by relatively unimpaired objective sleep -suggests a subtype of chronic insomnia. According to clinical guidelines, the diagnosis of primary insomnia is based mainly on subjective reports of poor sleep and adverse daytime consequences; objective PSG findings are not required, and the likelihood of psychological and psychosomatic symptoms is increased (25) . A meta-analysis of subjective and objective measures in primary insomnia revealed a disproportionate increase of PSQI-reported disturbance relative to PSG findings (26) . A previous evaluation of patients with TMD reported largely normal PSG findings in the context of elevated prevalence of primary insomnia diagnosis (17, 18) . The present study provides further evidence for subjectively poor sleep without clear objective findings in TMD cases, a pattern consistent with chronic insomnia. Therefore, while subjective reports of sleep disturbance in TMD should be taken with caution, clinical attention to the possibility of insomnia may still be warranted.
A strong relationship of self-reported poor sleep with depressive symptomatology but not objective PSG findings in the present sample is consistent with previous studies linking psychological symptoms and self-reported sleep in participants with and without TMD (2-4, 6, 7, 9, 13, 14) However, the mean SCL-90 depression score was only slightly elevated in TMD cases from the clinical viewpoint. Moreover, major depressive disorder is characterised by key PSG features, including reduced sleep efficiency, reduced stage N3 sleep, and abbreviated REM sleep latency (27) , which were absent in the present TMD 
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sample (19) . In fact, TMD cases demonstrated a tendency towards longer REM latency (19) , which presently was also associated with a modest increase in the PSQI. These findings suggest that self-reported depressive symptomatology in TMD may indicate a negative cognitive bias, perhaps related to chronic pain, rather than endogenous depression. Consistently, negative cognition may link depressive symptomatology with elevated PSQI scores in a non-pain population (14) .
A large longitudinal study assessing risk factors for the development of TMD revealed that the elevated PSQI and the subsequent reduction in subjective sleep quality predict future onset of TMD independently of stress or comorbid conditions (28) . However, perceived stress was shown to mediate the link between the PSQI and TMD onset, while the PSQI did not mediate the role of stress in TMD development (29) . Similarly, our findings underscore the importance of psychological variables in the PSQI-TMD relationship and suggest that differences in the baseline PSQI and subsequent sleep ratings preceding the TMD onset (28, 29) may not reflect differences in PSG-measured sleep parameters but represent negative cognitive bias and depressive symptomatology.
Limitations of the present study include selection of only women, the absence of clinical assessment for sleep and mood disorders, the absence of more subtle PSG measures of sleep disturbance, such as spectral power analysis of EEG, and the retrospective nature of subjective pain and sleep-related measures. A prospective study of patients with TMD indicates that reported symptoms of disturbed sleep appear to be better predictors of later pain experience than vice versa (30) . Therefore, further research, with prospective measurements of pain, sleep and psychological variables as well as more detailed analysis of physiological sleep data, may provide better understanding of the relationship and causal connections between sleep, pain and depressive symptomatology in myofascial patients with TMD. Employing multiple PSG assessments over time and matching for depressive symptomatology may be useful tools in future studies.
In sum, this study demonstrates that the increase in self-reported sleep problems in women with myofascial TMD is better attributed to depressive symptom reporting than to pain intensity or objective measures of sleep. These results caution against the assumption that myofascial pain is associated with an important change in more objective quantitative sleep outcome, as well as against the conclusion that self-report sleep measures accurately estimate the degree of objective sleep disturbance in patients with TMD.
